Symbols / CELU
CELU Chart
About
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 36.05M |
| Enterprise Value | 102.05M | Income | -80.65M | Sales | 40.58M |
| Book/sh | -0.71 | Cash/sh | 0.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 123 | IPO | — |
| P/E | — | Forward P/E | -2.19 | PEG | — |
| P/S | 0.89 | P/B | -1.76 | P/C | — |
| EV/EBITDA | -2.47 | EV/Sales | 2.52 | Quick Ratio | 0.10 |
| Current Ratio | 0.16 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.33 | EPS next Y | -0.57 | EPS Growth | — |
| Revenue Growth | -43.20% | Earnings | 2025-08-18 16:00 | ROA | -25.03% |
| ROE | — | ROIC | — | Gross Margin | 50.61% |
| Oper. Margin | -243.17% | Profit Margin | -198.75% | Shs Outstand | 28.84M |
| Shs Float | 18.07M | Short Float | 7.45% | Short Ratio | 10.80 |
| Short Interest | — | 52W High | 4.35 | 52W Low | 1.00 |
| Beta | 0.80 | Avg Volume | 55.71K | Volume | 53.51K |
| Target Price | — | Recom | None | Prev Close | $1.31 |
| Price | $1.25 | Change | -4.58% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.25
Latest analyst target
3. DCF / Fair value
$7.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.25
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-09 | up | WBB Securities | Hold → Buy | $6 |
| 2025-08-18 | init | WBB Securities | — → Speculative Buy | $6 |
- Celularity Inc. Secures $12.2 Million from Sale of New Jersey Net Operating Losses and R&D Tax Credits - Quiver Quantitative ue, 10 Feb 2026 08
- Retail investors among Celularity Inc.'s (NASDAQ:CELU) largest shareholders, saw gain in holdings value after stock jumped 11% last week - Yahoo Finance hu, 14 Aug 2025 07
- New Jersey tax program delivers $12.2M boost to Celularity - Stock Titan ue, 10 Feb 2026 08
- There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding - simplywall.st Mon, 15 Dec 2025 08
- Celularity Announces Closing of Financing Transactions - Investing News Network Mon, 22 Dec 2025 08
- Celularity stock drops after CMS withdraws skin substitute LCDs By Investing.com - Investing.com South Africa Fri, 26 Dec 2025 08
- Celularity Secures New Financing To Support Strategic Shift - TipRanks ue, 23 Dec 2025 08
- Is CELU stock forming a triangle pattern - Trade Risk Assessment & Weekly Momentum Picks - mfd.ru Sat, 21 Feb 2026 15
- Longevity-focused biotech Celularity raises $10M for aging research - Stock Titan Mon, 22 Dec 2025 08
- Gap Down: Is now the right time to enter CELU - Market Weekly Review & Expert Verified Movement Alerts - baoquankhu1.vn ue, 24 Feb 2026 14
- Celularity Inc. Faces Potential Delisting from Nasdaq Due to Fee and Filing Delinquencies - Nasdaq Fri, 25 Apr 2025 07
- Celularity Inc. Secures Up to $12 Million in Financing to Advance Strategic Priorities in Longevity and Human Performance - Quiver Quantitative hu, 18 Dec 2025 08
- Celularity Second Quarter 2025 Earnings: US$1.02 loss per share (vs US$0.30 loss in 2Q 2024) - simplywall.st Mon, 01 Sep 2025 07
- DoubleLine co-founder backs up to $12M funding plan for longevity - Stock Titan hu, 18 Dec 2025 08
- Celularity Inc. Comments on CMS Withdrawal of Skin Substitute Coverage Determinations - Quiver Quantitative Fri, 26 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 30000 | — | — | Stock Award(Grant) at price 0.00 per share. | PARKS DIANE L. | Director | — | 2026-01-12 00:00:00 | D |
| 1 | 20385 | — | — | Stock Award(Grant) at price 0.00 per share. | DIAMANDIS PETER | Director | — | 2026-01-12 00:00:00 | D |
| 2 | 19231 | — | — | Stock Award(Grant) at price 0.00 per share. | LING GEOFFREY M. D. | Director | — | 2026-01-12 00:00:00 | D |
| 3 | 28847 | — | — | Stock Award(Grant) at price 0.00 per share. | LEVIEN VINCENT | Director | — | 2026-01-12 00:00:00 | D |
| 4 | 125000 | — | — | Stock Award(Grant) at price 0.00 per share. | PARKS DIANE L. | Director | — | 2025-12-29 00:00:00 | D |
| 5 | 125000 | — | — | Stock Award(Grant) at price 0.00 per share. | DIAMANDIS PETER | Director | — | 2025-12-29 00:00:00 | D |
| 6 | 125000 | — | — | Stock Award(Grant) at price 0.00 per share. | LING GEOFFREY M. D. | Director | — | 2025-12-29 00:00:00 | D |
| 7 | 125000 | — | — | Stock Award(Grant) at price 0.00 per share. | LEVIEN VINCENT | Director | — | 2025-12-29 00:00:00 | D |
| 8 | 67416 | — | — | Stock Award(Grant) at price 0.00 per share. | PARKS DIANE L. | Director | — | 2025-12-19 00:00:00 | D |
| 9 | 67416 | — | — | Stock Award(Grant) at price 0.00 per share. | DIAMANDIS PETER | Director | — | 2025-12-19 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -40.39M | -74.30M | -141.13M | -142.74M |
| TotalUnusualItems | -3.32M | -109.64M | 164.78M | 54.63M |
| TotalUnusualItemsExcludingGoodwill | -3.32M | -109.64M | 164.78M | 54.63M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -57.89M | -196.29M | 14.19M | -100.12M |
| ReconciledDepreciation | 7.92M | 9.32M | 9.44M | 8.82M |
| ReconciledCostOfRevenue | 8.82M | 8.88M | 12.42M | 3.03M |
| EBITDA | -43.71M | -183.95M | 23.64M | -88.11M |
| EBIT | -51.63M | -193.27M | 14.21M | -96.93M |
| NetInterestIncome | -5.93M | -2.69M | 365.00K | -2.84M |
| InterestExpense | 6.26M | 3.02M | 0.00 | 3.17M |
| InterestIncome | 331.00K | 320.00K | 365.00K | 332.00K |
| NormalizedIncome | -54.58M | -86.65M | -150.58M | -154.75M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -57.89M | -196.29M | 14.19M | -100.12M |
| TotalExpenses | 92.77M | 99.25M | 166.24M | 171.54M |
| TotalOperatingIncomeAsReported | -38.36M | -192.29M | -25.60M | -109.06M |
| DilutedAverageShares | 21.89M | 17.81M | 14.98M | 6.71M |
| BasicAverageShares | 21.89M | 17.81M | 13.99M | 6.71M |
| DilutedEPS | -2.64 | -11.02 | 0.95 | -14.90 |
| BasicEPS | -2.64 | -11.02 | 1.01 | -14.90 |
| DilutedNIAvailtoComStockholders | -57.89M | -196.29M | 14.19M | -100.12M |
| NetIncomeCommonStockholders | -57.89M | -196.29M | 14.19M | -100.12M |
| NetIncome | -57.89M | -196.29M | 14.19M | -100.12M |
| NetIncomeIncludingNoncontrollingInterests | -57.89M | -196.29M | 14.19M | -100.12M |
| NetIncomeContinuousOperations | -57.89M | -196.29M | 14.19M | -100.12M |
| TaxProvision | 0.00 | 10.00K | 13.00K | 20.00K |
| PretaxIncome | -57.89M | -196.28M | 14.21M | -100.10M |
| OtherIncomeExpense | -13.41M | -117.11M | 162.11M | 52.95M |
| OtherNonOperatingIncomeExpenses | -10.09M | -7.47M | -2.67M | -1.68M |
| SpecialIncomeCharges | -3.71M | -115.81M | 122.67M | 41.15M |
| GainOnSaleOfBusiness | 0.00 | |||
| OtherSpecialCharges | 3.91M | |||
| WriteOff | 0.00 | 107.80M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 112.35M | 3.61M | 0.00 |
| RestructuringAndMergernAcquisition | -193.00K | -104.34M | -126.28M | -41.15M |
| GainOnSaleOfSecurity | 398.00K | 6.16M | 42.11M | 13.48M |
| NetNonOperatingInterestIncomeExpense | -5.93M | -2.69M | 365.00K | -2.84M |
| InterestExpenseNonOperating | 6.26M | 3.02M | 0.00 | 3.17M |
| InterestIncomeNonOperating | 331.00K | 320.00K | 365.00K | 332.00K |
| OperatingIncome | -38.55M | -76.48M | -148.27M | -150.20M |
| OperatingExpense | 77.78M | 83.23M | 146.58M | 161.89M |
| DepreciationAmortizationDepletionIncomeStatement | 1.75M | 2.19M | 2.19M | 2.19M |
| DepreciationAndAmortizationInIncomeStatement | 1.75M | 2.19M | 2.19M | 2.19M |
| Amortization | 1.75M | 2.19M | 2.19M | 2.19M |
| AmortizationOfIntangiblesIncomeStatement | 1.75M | 2.19M | 2.19M | 2.19M |
| ResearchAndDevelopment | 17.39M | 30.46M | 78.36M | 88.35M |
| SellingGeneralAndAdministration | 58.64M | 50.58M | 66.02M | 71.34M |
| GrossProfit | 39.23M | 6.75M | -1.69M | 11.68M |
| CostOfRevenue | 14.99M | 16.02M | 19.66M | 9.65M |
| TotalRevenue | 54.22M | 22.77M | 17.98M | 21.34M |
| OperatingRevenue | 54.22M | 22.77M | 17.98M | 21.34M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 22.55M | 19.38M | 14.89M | 12.43M |
| ShareIssued | 22.55M | 19.38M | 14.89M | 12.43M |
| NetDebt | 41.55M | 39.01M | 23.64M | |
| TotalDebt | 68.84M | 65.42M | 65.59M | 31.14M |
| TangibleBookValue | -7.76M | 22.61M | -41.79M | -147.07M |
| InvestedCapital | 51.12M | 80.20M | 236.50M | 99.42M |
| WorkingCapital | -33.12M | -47.51M | -28.59M | 32.88M |
| NetTangibleAssets | -7.76M | 22.61M | -41.79M | -147.07M |
| CapitalLeaseObligations | 26.55M | 26.18M | 27.98M | 31.14M |
| CommonStockEquity | 8.84M | 40.96M | 198.90M | 99.42M |
| TotalCapitalization | 44.76M | 40.96M | 198.90M | 99.42M |
| TotalEquityGrossMinorityInterest | 8.84M | 40.96M | 198.90M | 99.42M |
| StockholdersEquity | 8.84M | 40.96M | 198.90M | 99.42M |
| GainsLossesNotAffectingRetainedEarnings | -5.00K | 0.00 | 9.00K | 0.00 |
| OtherEquityAdjustments | -5.00K | 9.00K | ||
| TreasuryStock | 0.00 | |||
| RetainedEarnings | -899.68M | -841.79M | -645.50M | -663.68M |
| AdditionalPaidInCapital | 908.52M | 882.73M | 844.37M | 763.09M |
| CapitalStock | 2.00K | 19.00K | 15.00K | 12.00K |
| CommonStock | 2.00K | 19.00K | 15.00K | 12.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 123.84M | 102.93M | 202.16M | 314.71M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 70.17M | 35.63M | 140.08M | 288.49M |
| OtherNonCurrentLiabilities | 1.69M | 1.90M | 106.27M | 232.56M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| DerivativeProductLiabilities | 3.26M | 4.36M | 3.60M | 25.96M |
| NonCurrentDeferredLiabilities | 2.73M | 3.19M | 2.23M | 1.88M |
| NonCurrentDeferredRevenue | 2.72M | 3.19M | 2.22M | 1.87M |
| NonCurrentDeferredTaxesLiabilities | 9.00K | 9.00K | 9.00K | 10.00K |
| LongTermDebtAndCapitalLeaseObligation | 62.48M | 26.18M | 27.98M | 28.09M |
| LongTermCapitalLeaseObligation | 26.55M | 26.18M | 27.98M | 28.09M |
| LongTermDebt | 35.93M | |||
| CurrentLiabilities | 53.68M | 67.30M | 62.09M | 26.23M |
| OtherCurrentLiabilities | 1.60M | 2.45M | 2.63M | 4.32M |
| CurrentDeferredLiabilities | 3.53M | 2.83M | 2.27M | 2.20M |
| CurrentDeferredRevenue | 3.53M | 2.83M | 2.27M | 2.20M |
| CurrentDebtAndCapitalLeaseObligation | 6.36M | 39.24M | 37.60M | 3.05M |
| CurrentCapitalLeaseObligation | 0.00 | 3.05M | ||
| CurrentDebt | 6.36M | 39.24M | 37.60M | |
| OtherCurrentBorrowings | 6.36M | 39.24M | 37.60M | |
| PayablesAndAccruedExpenses | 42.18M | 22.78M | 19.58M | 16.66M |
| CurrentAccruedExpenses | 18.89M | 8.63M | 13.77M | 7.34M |
| InterestPayable | 1.80M | 0.00 | ||
| Payables | 23.30M | 14.14M | 5.81M | 9.32M |
| AccountsPayable | 23.30M | 14.14M | 5.81M | 9.32M |
| TotalAssets | 132.68M | 143.89M | 401.07M | 414.13M |
| TotalNonCurrentAssets | 112.12M | 124.10M | 367.56M | 355.03M |
| OtherNonCurrentAssets | 23.10M | 26.93M | 38.16M | 17.91M |
| GoodwillAndOtherIntangibleAssets | 16.59M | 18.35M | 240.69M | 246.49M |
| OtherIntangibleAssets | 9.25M | 11.00M | 120.99M | 123.19M |
| Goodwill | 7.35M | 7.35M | 119.69M | 123.30M |
| NetPPE | 72.43M | 78.82M | 88.72M | 90.62M |
| AccumulatedDepreciation | -32.87M | -27.28M | -20.33M | -14.78M |
| GrossPPE | 105.30M | 106.10M | 109.05M | 105.40M |
| Leases | 73.21M | 73.21M | 70.11M | 71.47M |
| ConstructionInProgress | 0.00 | 21.00K | 3.66M | 2.05M |
| OtherProperties | 24.92M | 25.08M | 27.49M | 11.39M |
| MachineryFurnitureEquipment | 7.16M | 7.78M | 7.78M | 7.97M |
| BuildingsAndImprovements | 0.00 | 12.51M | ||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 20.56M | 19.79M | 33.50M | 59.10M |
| OtherCurrentAssets | 261.00K | 329.00K | 1.05M | 2.00K |
| PrepaidAssets | 596.00K | 1.37M | 6.21M | 7.08M |
| Inventory | 5.41M | 5.75M | 5.31M | 9.55M |
| Receivables | 13.56M | 12.12M | 6.97M | 5.23M |
| NotesReceivable | 0.00 | 2.07M | 2.51M | 2.49M |
| AccountsReceivable | 13.56M | 10.05M | 4.45M | 2.75M |
| AllowanceForDoubtfulAccountsReceivable | -6.29M | -5.84M | -1.79M | -283.00K |
| GrossAccountsReceivable | 19.85M | 15.88M | 6.24M | 3.03M |
| CashCashEquivalentsAndShortTermInvestments | 738.00K | 227.00K | 13.97M | 37.24M |
| CashAndCashEquivalents | 738.00K | 227.00K | 13.97M | 37.24M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.56M | -42.73M | -143.11M | -116.30M |
| RepurchaseOfCapitalStock | 0.00 | |||
| RepaymentOfDebt | -17.52M | -16.81M | 0.00 | -5.00M |
| IssuanceOfDebt | 3.62M | 2.00M | 85.69M | 5.00M |
| IssuanceOfCapitalStock | 6.00M | 21.89M | 36.52M | 83.40M |
| CapitalExpenditure | -161.00K | -4.05M | -5.24M | -6.20M |
| InterestPaidSupplementalData | 144.00K | 1.07M | 0.00 | 146.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 10.98M | 10.16M | 28.80M | 52.08M |
| BeginningCashPosition | 10.16M | 28.80M | 52.08M | 69.51M |
| ChangesInCash | 814.00K | -18.64M | -23.27M | -17.44M |
| FinancingCashFlow | 6.70M | 24.09M | 119.84M | 98.56M |
| CashFlowFromContinuingFinancingActivities | 6.70M | 24.09M | 119.84M | 98.56M |
| NetOtherFinancingCharges | -459.00K | -1.65M | -3.23M | 9.14M |
| ProceedsFromStockOptionExercised | 15.06M | 18.67M | 862.00K | 6.02M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 6.00M | 21.89M | 36.52M | 83.40M |
| CommonStockPayments | 0.00 | |||
| CommonStockIssuance | 6.00M | 21.89M | 36.52M | 83.40M |
| NetIssuancePaymentsOfDebt | -13.90M | -14.81M | 85.69M | 0.00 |
| NetShortTermDebtIssuance | -13.90M | -14.81M | 39.20M | 0.00 |
| ShortTermDebtPayments | -17.52M | -16.81M | 0.00 | -5.00M |
| ShortTermDebtIssuance | 3.62M | 2.00M | 39.20M | 5.00M |
| NetLongTermDebtIssuance | 17.37M | 46.49M | ||
| LongTermDebtIssuance | 17.37M | 46.49M | ||
| InvestingCashFlow | 514.00K | -4.05M | -5.24M | -5.90M |
| CashFlowFromContinuingInvestingActivities | 514.00K | -4.05M | -5.24M | -5.90M |
| NetOtherInvestingChanges | 2.17M | 300.00K | ||
| NetBusinessPurchaseAndSale | -1.50M | 0.00 | 0.00 | |
| SaleOfBusiness | 0.00 | |||
| PurchaseOfBusiness | -1.50M | 0.00 | ||
| NetIntangiblesPurchaseAndSale | 0.00 | -3.00M | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -3.00M | 0.00 | |
| CapitalExpenditureReported | -161.00K | -1.05M | -5.24M | -6.20M |
| OperatingCashFlow | -6.40M | -38.69M | -137.88M | -110.10M |
| CashFlowFromContinuingOperatingActivities | -6.40M | -38.69M | -137.88M | -110.10M |
| ChangeInWorkingCapital | 22.20M | 3.25M | -17.98M | -11.08M |
| ChangeInOtherWorkingCapital | 606.00K | 1.80M | 688.00K | -7.03M |
| ChangeInPayablesAndAccruedExpense | 18.37M | 3.54M | 1.76M | 1.21M |
| ChangeInAccruedExpense | 9.13M | -4.96M | 4.71M | -1.80M |
| ChangeInPayable | 9.24M | 8.50M | -2.95M | 3.01M |
| ChangeInAccountPayable | 9.24M | 8.50M | -2.95M | 3.01M |
| ChangeInPrepaidAssets | 905.00K | 5.61M | 49.00K | 3.07M |
| ChangeInInventory | 6.28M | -865.00K | -16.89M | -6.42M |
| ChangeInReceivables | -3.97M | -6.83M | -3.58M | -1.91M |
| ChangesInAccountReceivables | -3.97M | -6.83M | -3.58M | -1.91M |
| OtherNonCashItems | 5.39M | -92.31M | -123.67M | -33.19M |
| StockBasedCompensation | 11.73M | 15.02M | 15.86M | 40.01M |
| ProvisionandWriteOffofAssets | 271.00K | 2.56M | 1.88M | 298.00K |
| AssetImpairmentCharge | 466.00K | 225.53M | 4.51M | 0.00 |
| DeferredTax | 0.00 | -1.00K | -1.35M | |
| DeferredIncomeTax | 0.00 | -1.00K | -1.35M | |
| DepreciationAmortizationDepletion | 7.92M | 9.32M | 9.44M | 8.82M |
| DepreciationAndAmortization | 7.92M | 9.32M | 9.44M | 8.82M |
| AmortizationCashFlow | 1.75M | 2.19M | ||
| AmortizationOfIntangibles | 1.75M | 2.19M | ||
| Depreciation | 6.17M | 7.13M | ||
| OperatingGainsLosses | 3.51M | -5.76M | -42.11M | -13.48M |
| GainLossOnInvestmentSecurities | -398.00K | -5.76M | -42.11M | -13.48M |
| GainLossOnSaleOfBusiness | 0.00 | |||
| NetIncomeFromContinuingOperations | -57.89M | -196.29M | 14.19M | -100.12M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CELU
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|